Role of Nitric Oxide-Releasing Chitosan Oligosaccharides on Mucus Viscoelasticity
Source abstract
Abstract
Nitric oxide (NO)-releasing chitosan oligosaccharides were modified with ester functional groups to examine how the mucoadhesive nature of the scaffold impacts the ability of NO to degrade mucins from human bronchial epithelial cell cultures and clinical sputum samples collected from patients with cystic fibrosis (CF). Agarose gel electrophoresis experiments indicated that the mucoadhesive NO-releasing chitosan oligosaccharides degraded both the purified mucins and sputum, while control scaffolds (without NO release or mucoadhesive ligands) had no effect on mucin structure. Microscopic observations of sputum treated with the mucoadhesive NO-releasing chitosan oligosaccharide confirmed degradation of the mucin and DNA networks. Similarly, the viscosity and elasticity of sputum were reduced upon treatment with the mucoadhesive NO-releasing chitosan, demonstrating the potential utility of these NO-releasing scaffolds as mucolytic agents.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cystic Fibrosis Research Advances · Nanocomposite Films for Food Packaging · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, University of North Carolina-Chapel Hill, 131 South Road, Chapel Hill, North Carolina 27599, United States
Marsico Lung Institute, University of North Carolina-Chapel Hill, 125 Mason Farm Road, Chapel Hill, North Carolina 27599, United States
Department of Pediatrics, University of North Carolina-Chapel Hill School of Medicine, 206 MacNider Building, Chapel Hill, North Carolina 27599, United Sates
Department of Physics and Astronomy, University of North Carolina-Chapel Hill, 120 E. Cameron Avenue, Chapel Hill, North Carolina 27599, United States
Funding
Division of Mathematical Sciences · National Heart, Lung, and Blood Institute · National Institute of Allergy and Infectious Diseases · Cystic Fibrosis Foundation
References (56)
Show source-provided references
1. 10.1186/1741-7015-9-3210.1186/1741-7015-9-32 ↗
2. 10.1002/ppul.2066510.1002/ppul.20665 ↗
3. 10.1016/j.biocel.2014.03.01110.1016/j.biocel.2014.03.011 ↗
4. 10.1073/pnas.060642810310.1073/pnas.0606428103 ↗
5. 10.1016/S0169-409X(02)00152-710.1016/S0169-409X(02)00152-7 ↗
6. 10.1128/CMR.15.2.194-222.200210.1128/CMR.15.2.194-222.2002 ↗
7. 10.1128/AAC.01208-1510.1128/AAC.01208-15 ↗
8. 10.1080/08927014.2015.110754810.1080/08927014.2015.1107548 ↗
9. 10.1016/S1773-2247(10)50004-210.1016/S1773-2247(10)50004-2 ↗
10. 10.1016/j.progpolymsci.2011.02.00110.1016/j.progpolymsci.2011.02.001 ↗
11. 10.1016/j.addr.2009.09.00410.1016/j.addr.2009.09.004 ↗
12. 10.1021/bm500795410.1021/bm5007954 ↗
13. 10.1021/bm800276d10.1021/bm800276d ↗
14. 10.1517/17425247.2015.100794910.1517/17425247.2015.1007949 ↗
15. 10.1016/j.colsurfb.2007.10.00510.1016/j.colsurfb.2007.10.005 ↗
16. 10.1016/j.ijpharm.2012.10.04410.1016/j.ijpharm.2012.10.044 ↗
17. 10.1002/jbm.b.3099410.1002/jbm.b.30994 ↗
18. 10.1016/j.ijpharm.2013.04.00910.1016/j.ijpharm.2013.04.009 ↗
19. 10.1016/j.jconrel.2011.08.01010.1016/j.jconrel.2011.08.010 ↗
20. 10.2217/nnm.10.12310.2217/nnm.10.123 ↗
21. 10.1073/pnas.090599810610.1073/pnas.0905998106 ↗
22. 10.2217/nnm.12.12910.2217/nnm.12.129 ↗
23. 10.1016/j.biomaterials.2008.12.07610.1016/j.biomaterials.2008.12.076 ↗
24. 10.1007/978-1-61779-513-8_1510.1007/978-1-61779-513-8_15 ↗
25. 10.1016/j.biomaterials.2013.11.01510.1016/j.biomaterials.2013.11.015 ↗
26. 10.1002/macp.1988.02189011810.1002/macp.1988.021890118 ↗
27. 10.3791/5415310.3791/54153 ↗
28. 10.1186/1465-9921-13-9810.1186/1465-9921-13-98 ↗
29. 10.1039/c2cs15272j10.1039/c2cs15272j ↗
30. 10.1021/cr000028t10.1021/cr000028t ↗
31. 10.1021/cr000040l10.1021/cr000040l ↗
32. 10.1016/S0928-0987(00)00065-810.1016/S0928-0987(00)00065-8 ↗
33. 10.1016/S0928-0987(00)00194-910.1016/S0928-0987(00)00194-9 ↗
34. 10.1002/mabi.20100038810.1002/mabi.201000388 ↗
35. 10.1164/rccm.200607-1011OC10.1164/rccm.200607-1011OC ↗
36. 10.1039/c2cs15273h10.1039/c2cs15273h ↗
37. 10.1021/bm400961r10.1021/bm400961r ↗
38. 10.1021/bm301109c10.1021/bm301109c ↗
39. 10.1021/acs.molpharmaceut.5b0000610.1021/acs.molpharmaceut.5b00006 ↗
40. 10.1021/nn700191f10.1021/nn700191f ↗
41. 10.1021/nn202054f10.1021/nn202054f ↗
42. 10.1021/am402618w10.1021/am402618w ↗
43. 10.1021/bm301108x10.1021/bm301108x ↗
44. 10.1172/JCI7346910.1172/JCI73469 ↗
45. 10.1016/j.carbpol.2008.07.00510.1016/j.carbpol.2008.07.005 ↗
46. 10.1164/rccm.201412-2230OC10.1164/rccm.201412-2230OC ↗
47. 10.1016/j.addr.2008.09.01210.1016/j.addr.2008.09.012 ↗
48. 10.1136/thx.51.2.11910.1136/thx.51.2.119 ↗
49. 10.1021/tx960031110.1021/tx9600311 ↗
50. 10.1016/S0027-5107(99)00006-810.1016/S0027-5107(99)00006-8 ↗
51. 10.1093/glycob/cwq17110.1093/glycob/cwq171 ↗
52. 10.1023/A:100594842054810.1023/A:1005948420548 ↗
53. 10.1177/002203451558931410.1177/0022034515589314 ↗
54. 10.1016/j.biotechadv.2015.01.00510.1016/j.biotechadv.2015.01.005 ↗
55. 10.1007/s00253-010-2733-x10.1007/s00253-010-2733-x ↗
56. 10.1007/s15010-016-0879-x10.1007/s15010-016-0879-x ↗